Temozolomide Market Size, Share & Growth Statistics Report to 2030

Temozolomide Market Size, Share, Growth Trends, Industry Analysis and Forecast to 2030

Report ID: RC82156 | Report Format: PDF + Excel | Last Updated: September 3rd, 2025

The global temozolomide market size was valued at around USD 1 billion in 2024 and estimated to register a significant CAGR of around 3% during the forecast period from 2025 to 2030. The increasing incidence of brain cancer around the world is a primary factor to drive the market growth. According to the information shared by the American Cancer Society, 308,102 new cases have reported as brain and nervous system cancer in 2020 around the world. Furthermore, the market is accelerated by the effective implementation of treatment guidelines related to the management and treatment of malignant brain tumors. Temozolomide is classified as an antinoplastic drug widely used by neurologists for the treatment of refractory anaplastic astrocytoma.

Report Attributes:

Benchmark Year		2024
Market Size		~ USD 1 Billion in 2024
Market Growth (CAGR)		~ 3% (2025-2030)
Largest Market Share
Analysis Period		2020-2030
Market Players		Accord Healthcare, Inc., Apotex Corporation, Merck KGaA, Cipla Limited., and Teva Pharmaceutical Industries Limited

Temozolomide Market Key Drivers:

The temozolomide market is primarily driven by the rising prevalence of brain cancers, particularly glioblastoma multiforme (GBM), and other central nervous system (CNS) tumors. Temozolomide is widely recognized as the first-line chemotherapeutic agent for treating GBM due to its ability to cross the blood-brain barrier effectively, offering better treatment outcomes compared to many alternatives. With cancer incidence rates climbing globally, coupled with improved diagnostic technologies, the number of patients eligible for temozolomide therapy is steadily increasing. This demand is further reinforced by the growing adoption of combination therapies, where temozolomide is used alongside radiotherapy to enhance survival rates.

Another key driver is the expansion of clinical research and regulatory support for oncology drugs. Continuous research into temozolomide’s efficacy in treating various cancers, including metastatic melanoma and other rare malignancies, is widening its therapeutic scope. The presence of strong reimbursement frameworks and healthcare infrastructure in developed regions further supports its adoption. Additionally, the increasing availability of generic versions of temozolomide has improved affordability and accessibility, especially in emerging economies, allowing more patients to benefit from this vital oncology treatment and fueling global market growth.

Industry Trends Shaping the Temozolomide Market:

The temozolomide market is witnessing a strong trend toward the increasing use of generics, as patents for branded versions like Temodar have expired in many regions. Generic temozolomide has significantly reduced treatment costs, improving accessibility for patients in both developed and emerging markets. This shift has intensified competition among pharmaceutical manufacturers, encouraging expansion into new geographies and creating opportunities for local and regional players. The rise in generic adoption is also driving collaborations between governments and healthcare providers to improve cancer treatment affordability and availability.

Another key trend is the integration of temozolomide into innovative treatment regimens through combination therapies and research in precision medicine. Clinical trials are exploring temozolomide alongside immunotherapies, targeted therapies, and radiotherapy to improve survival outcomes in glioblastoma and other aggressive cancers. Advances in personalized medicine are also influencing dosing strategies and patient selection, enhancing the effectiveness of treatment. Furthermore, ongoing R&D into novel delivery systems, such as nanoparticle-based drug carriers, aims to improve bioavailability and reduce side effects, positioning temozolomide as a cornerstone therapy within evolving oncology treatment protocols.

Temozolomide Market Opportunities:

The temozolomide market offers significant opportunities through the expansion of treatment applications beyond glioblastoma. While it is primarily used for glioblastoma multiforme, ongoing research is evaluating its effectiveness in other cancers such as metastatic melanoma, astrocytoma, and rare pediatric tumors. Positive clinical outcomes in these areas could broaden its therapeutic scope and strengthen market demand. Additionally, the integration of temozolomide with advanced cancer treatment modalities like immunotherapies and targeted therapies presents new opportunities for synergistic treatment regimens, improving patient outcomes and survival rates.

Another major opportunity lies in the growth of emerging markets, where rising cancer incidence and improving healthcare infrastructure are driving demand for cost-effective treatments. The availability of generic temozolomide at lower prices makes it more accessible in low- and middle-income countries, supporting wider patient adoption. Furthermore, pharmaceutical companies investing in novel drug delivery technologies—such as sustained-release formulations and nanoparticle carriers—can differentiate their products and capture premium market segments. Strategic collaborations between research institutions, pharmaceutical companies, and healthcare providers also create pathways for innovation and expanded commercialization, enhancing temozolomide’s role in global oncology care.

Market Segments Insights:

The global temozolomide market is bifurcated into clinical application, distribution channel, and geography. On the basis of clinical application, the market if further segmented into glioblastoma multiforme, anaplastic astrocytoma, and others. The glioblastoma multiforme segment is accounted to hold the largest market share by revenue. The glioblastoma industry is accounted to grow at sustainable growth rate around 8%, which is expected to drive the segment growth over the forecast period. Furthermore, according to the information shared by the National Institute of Health (NIH), the incidence rate associated with glioblastoma multiforme is 2 to 3 per 100,000 adults globally.

Moreover, the anaplastic astrocytoma segment is accounted to grow at a significant growth rate over the forecast period. As per the latest research shared by American Cancer Society (ACS), the anaplastic astrocytoma accounts for 1% to 2% of primary brain tumors across the globe.

On the basis of distribution channel, the temozolomide market is classified into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment is accounted to dominate the global market and expected to grow at the same trend over the forecast period. The drug is considered as an adjunctive therapy agent for patients with brain tumors subject to radiation therapy, therefore accurate drug delivery is necessary under the supervision of a hospital pharmacist to prevent the occurrence of unwanted side effects associated with temozolomide.

The temozolomide comprehensive study offers an in-depth analysis of industry trends, market size, competitive analysis, and market forecast – 2025 to 2030. Research Corridor report provides detailed premium insight into the global market and reveals the potential revenue streams, commercial prospects, market drivers, challenges, opportunities, issues, and events affecting the industry. In addition, the report has a dedicated section covering market forecasts and analysis for leading geographies, profiles of major companies operating in the market and expert opinion obtained from interviews with industry executives and experts from prominent companies.

Temozolomide Market Segmentation:

By Clinical Application:

Glioblastoma Multiforme
Anaplastic Astrocytoma
Others

By Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Others

By Region:

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Geographic Coverage

Geographically, the temozolomide market report comprises dedicated sections centering on the regional market revenue and trends. The market has been segmented on the basis of geographic regions into North America, Europe, Asia Pacific, and Rest of the World (RoW). The RoW segment consists of Latin America and the Middle East & Africa. The market has been extensively analyzed on the basis of various regional factors such as demographics, gross domestic product (GDP), inflation rate, acceptance, and others. The market estimates have also been provided for the historical years along with forecasts for the period from 2025 – 2030.

Temozolomide Market Competition Assessment

Key players operating in the global temozolomide market are Accord Healthcare, Inc., Apotex Corporation, Merck KGaA, Cipla Limited., and Teva Pharmaceutical Industries Limited. Companies are exploring markets by expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

Key Companies:

Accord Healthcare, Inc.
Apotex Corporation
Merck KGaA
Cipla Limited.
Teva Pharmaceutical Industries Limited.
Schering-Plough Corporation
Mayne Pharma Group
Alvogen
Mylan Pharmaceutical Industries Limited
Sandoz, Inc.

Key Questions Answered by Temozolomide Market Report:

Global temozolomide market forecasts from 2025-2030
Regional temozolomide market forecasts from 2025-2030 covering Asia-Pacific, North America, Europe, Middle East and Africa, and Latin America
Country-level forecasts from 2025-2030 covering 15 major countries from the aforementioned regions
Temozolomide submarket forecasts from 2025-2030 covering the market by clinical application, by distribution channel, and geography
Various industry models such as SWOT analysis, Value Chain Analysis pertaining to market
Analysis of the key factors driving and restraining the growth of the global, regional and country-level markets from 2025-2030
Competitive Landscape and market positioning of top 10 players operating in the market

Table of Content:

1. Preface

1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.4. Assumptions

2. Executive Summary

2.1. Global Temozolomide Market Portraiture
2.2. Global Temozolomide Market, by Clinical Application, 2020 (USD Mn)
2.3. Global Temozolomide Market, by Distribution Channel, 2020 (USD Mn)
2.4. Global Temozolomide Market, by Geography, 2020 (USD Mn)

3. Global Temozolomide Market Analysis

3.1. Temozolomide Market Overview
3.2. Market Inclination Insights
3.3. Market Dynamics
3.3.1. Drivers
3.3.2. Challenges
3.3.3. Opportunities
3.4. Attractive Investment Proposition
3.5. Competitive Analysis
3.6. COVID-19 Impact Analysis
3.6.1. V Shaped Recovery
3.6.2. U Shaped Recovery
3.6.3. L Shaped Recovery
3.6.4. W Shaped Recovery

4. Global Temozolomide Market By Clinical Application, 2018 – 2027 (USD Mn)

4.1. Overview
4.2. Glioblastoma Multiforme
4.3. Anaplastic Astrocytoma
4.4. Others

5. Global Temozolomide Market By Distribution Channel, 2018 – 2027 (USD Mn)

5.1. Overview
5.2. Hospital Pharmacy
5.3. Retail Pharmacy
5.4. Others

6. North America Temozolomide Market Analysis and Forecast, 2018 – 2027 (USD Mn)

6.1.1. Overview
6.1.2. North America Temozolomide Market by Clinical Application (2018-2027 USD Mn)
6.1.3. North America Temozolomide Market by Distribution Channel (2018-2027 USD Mn)
6.1.4. North America Temozolomide Market by Country (2018-2027 USD Mn)
6.1.4.1. U.S.
6.1.4.2. Canada

7. Europe Temozolomide Market Analysis and Forecast, 2018 – 2027 (USD Mn)

7.1.1. Overview
7.1.2. Europe Temozolomide Market by Clinical Application (2018-2027 USD Mn)
7.1.3. Europe Temozolomide Market by Distribution Channel (2018-2027 USD Mn)
7.1.4. Europe Temozolomide Market by Country (2018-2027 USD Mn)
7.1.4.1. Germany
7.1.4.2. U.K.
7.1.4.3. France
7.1.4.4. Italy
7.1.4.5. Rest of Europe

8. Asia Pacific Temozolomide Market Analysis and Forecast, 2018 – 2027 (USD Mn)

8.1.1. Overview
8.1.2. Asia Pacific Temozolomide Market by Clinical Application (2018-2027 USD Mn)
8.1.3. Asia Pacific Temozolomide Market by Distribution Channel (2018-2027 USD Mn)
8.1.4. Asia Pacific Temozolomide Market by Country (2018-2027 USD Mn)
8.1.4.1. China.
8.1.4.2. Japan
8.1.4.3. Rest of Asia Pacific

9. Latin America (LATAM) Temozolomide Market Analysis and Forecast, 2018 – 2027 (USD Mn)

9.1.1. Overview
9.1.2. Latin America Temozolomide Market by Clinical Application (2018-2027 USD Mn)
9.1.3. Latin America Temozolomide Market by Distribution Channel (2018-2027 USD Mn)
9.1.4. Latin America Temozolomide Market by Country (2018-2027 USD Mn)
9.1.4.1. Brazil
9.1.4.2. Mexico
9.1.4.3. Rest of Latin America

10. Middle East and Africa Temozolomide Market Analysis and Forecast, 2018 – 2027 (USD Mn)

10.1.1. Overview
10.1.2. MEA Temozolomide Market by Clinical Application (2018-2027 USD Mn)
10.1.3. MEA Temozolomide Market by Distribution Channel (2018-2027 USD Mn)
10.1.4. Middle East and Africa Temozolomide Market, by Country (2018-2027 USD Mn)
10.1.4.1. GCC
10.1.4.2. Rest of MEA

11. Company Profiles

11.1. Accord Healthcare, Inc.
11.1.1. Business Description
11.1.2. Financial Health and Budget Allocation
11.1.3. Product Positions/Portfolio
11.1.4. Recent Development
11.1.5. SWOT Analysis
11.2. Apotex Corporation
11.2.1. Business Description
11.2.2. Financial Health and Budget Allocation
11.2.3. Product Positions/Portfolio
11.2.4. Recent Development
11.2.5. SWOT Analysis
11.3. Merck KGaA
11.3.1. Business Description
11.3.2. Financial Health and Budget Allocation
11.3.3. Product Positions/Portfolio
11.3.4. Recent Development
11.3.5. SWOT Analysis
11.4. Cipla Limited
11.4.1. Business Description
11.4.2. Financial Health and Budget Allocation
11.4.3. Product Positions/Portfolio
11.4.4. Recent Development
11.4.5. SWOT Analysis
11.5. Teva Pharmaceutical Industries Limited
11.5.1. Business Description
11.5.2. Financial Health and Budget Allocation
11.5.3. Product Positions/Portfolio
11.5.4. Recent Development
11.5.5. SWOT Analysis
11.6. Schering-Plough Corporation
11.6.1. Business Description
11.6.2. Financial Health and Budget Allocation
11.6.3. Product Positions/Portfolio
11.6.4. Recent Development
11.6.5. SWOT Analysis
11.7. Mayne Pharma Group
11.7.1. Business Description
11.7.2. Financial Health and Budget Allocation
11.7.3. Product Positions/Portfolio
11.7.4. Recent Development
11.7.5. SWOT Analysis
11.8. Alvogen
11.8.1. Business Description
11.8.2. Financial Health and Budget Allocation
11.8.3. Product Positions/Portfolio
11.8.4. Recent Development
11.8.5. SWOT Analysis
11.9. Mylan Pharmaceutical Industries Limited
11.9.1. Business Description
11.9.2. Financial Health and Budget Allocation
11.9.3. Product Positions/Portfolio
11.9.4. Recent Development
11.9.5. SWOT Analysis
11.10. Sandoz, Inc.
11.10.1. Business Description
11.10.2. Financial Health and Budget Allocation
11.10.3. Product Positions/Portfolio
11.10.4. Recent Development
11.10.5. SWOT Analysis

To know more about the study, request a report sample

List of Tables:

TABLE 1 Market Snapshot: Global Temozolomide Market

TABLE 2 Impact Indicators

TABLE 3 Impact Analysis of Drivers and Challenges

TABLE 4 Global Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 5 Global Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 6 North America Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 7 North America Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 8 North America Temozolomide Market Value, By Country, 2018 - 2027 (US$ Mn)

TABLE 9 U.S. Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 10 U.S. Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 11 Canada Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 12 Canada Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 13 Europe Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 14 Europe Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 15 Europe Temozolomide Market Value, by Country, 2018 - 2027 (US$ Mn)

TABLE 16 Germany Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 17 Germany Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 18 U.K. Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 19 U.K. Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 20 France Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 21 France Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 22 Italy Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 23 Italy Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 24 Rest of Europe Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 25 Rest of Europe Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 26 Asia Pacific Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 27 Asia Pacific Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 28 Asia Pacific Temozolomide Market Value, by Country, 2018 - 2027 (US$ Mn)

TABLE 29 Japan Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 30 Japan Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 31 China Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 32 China Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 33 Rest of Asia Pacific Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 34 Rest of Asia Pacific Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 35 Latin America Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 36 Latin America Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 37 Latin America Temozolomide Market Value, by Country, 2018 - 2027 (US$ Mn)

TABLE 38 Brazil Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 39 Brazil Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 40 Mexico Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 41 Mexico Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 42 Rest of Latin America Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 43 Rest of Latin America Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 44 Middle East & Africa Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 45 Middle East & Africa Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 46 Middle East & Africa Temozolomide Market Value, by Country, 2018 - 2027 (US$ Mn)

TABLE 47 GCC Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 48 GCC Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 49 Rest of MEA Temozolomide Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 50 Rest of MEA Temozolomide Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 51 Accord Healthcare, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent Developments)

TABLE 52 Apotex Corporation: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent Developments)

TABLE 53 Merck KGaA: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent Developments)

TABLE 54 Cipla Limited: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent Developments)

TABLE 55 Teva Pharmaceutical Industries Limited: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent Developments)

TABLE 56 Schering-Plough Corporation: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent Developments)

TABLE 57 Mayne Pharma Group: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent Developments)

TABLE 58 Alvogen: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent Developments)

TABLE 59 Mylan Pharmaceutical Industries Limited: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent Developments)

TABLE 60 Sandoz, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent Developments)

To know more about the study, request a report sample

List of Figures:

FIG. 1 Global Temozolomide: Market Segmentation

FIG. 2 Global Temozolomide Market: Research Methodology

FIG. 3 Top-Down and Bottom-up Approach

FIG. 4 Global Temozolomide Market, by Clinical Application, 2019 (US$ Mn)

FIG. 5 Global Temozolomide Market, by Distribution Channel, 2019 (US$ Mn)

FIG. 6 Global Temozolomide Market, by Geography, 2019 (US$ Mn)

FIG. 7 Global Temozolomide Market Value and Growth, 2018 – 2027, (US$ Mn) (Y-o-Y %)

FIG. 8 Attractive Investment Proposition, by Geography, 2017

FIG. 9 Market Positioning of Key Temozolomide Providers, 2019

FIG. 10 Global Temozolomide Market Value Share, by Clinical Application, 2018 & 2027 (%)

FIG. 11 Global Temozolomide Market Value for Glioblastoma Multiforme, 2018 - 2027, (US$ Mn)

FIG. 12 Global Temozolomide Market Value for Anaplastic Astrocytoma, 2018 - 2027, (US$ Mn)

FIG. 13 Global Temozolomide Market Value for Others, 2018 - 2027, (US$ Mn)

FIG. 14 Global Temozolomide Market Value Share, by Distribution Channel, 2018 & 2027 (Value %)

FIG. 15 Global Temozolomide Market Value for Hospital Pharmacy, 2018 - 2027, (US$ Mn)

FIG. 16 Global Temozolomide Market Value for Retail Pharmacy, 2018 - 2027, (US$ Mn)

FIG. 17 Global Temozolomide Market Value for Others, 2018 - 2027, (US$ Mn)

FIG. 18 North America Temozolomide Market Value, 2018 - 2027, (US$ Mn)

FIG. 19 Europe Temozolomide Market Value, 2018 - 2027, (US$ Mn)

FIG. 20 Asia Pacific Temozolomide Market Value, 2018 - 2027, (US$ Mn)

FIG. 21 LATIN America Temozolomide Market Value, 2018 - 2027, (US$ Mn)

FIG. 22 Middle East & Africa Temozolomide Market Value, 2018 - 2027, (US$ Mn)

Fill the given form to inquiry before buying for Temozolomide Market Report

Download Sample Papers

Inquiry Before Buying

Schedule a Call

Select License Type

$ 2450/- Single User License
$ 5200/- Multi User License
$ 6950/- Corporate License